

# Heart Failure With Preserved Ejection Fraction and Di

Journal of the American College of Cardiology

73, 602-611

DOI: [10.1016/j.jacc.2018.11.033](https://doi.org/10.1016/j.jacc.2018.11.033)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3264.	1.8	93
2	Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives. <i>Diagnostics</i> , 2019, 9, 121.	1.3	21
3	Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies. <i>Journal of Clinical Medicine</i> , 2019, 8, 792.	1.0	32
4	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 399-414.	0.9	26
5	Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 823-834.	1.3	9
6	Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. <i>Circulation</i> , 2020, 142, 1246-1248.	1.6	0
7	Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 27-34.	0.8	38
8	Advances in Exosomes Derived from Different Cell Sources and Cardiovascular Diseases. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	8
9	Osteopontin and LDLR Are Upregulated in Hearts of Sudden Cardiac Death Victims With Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 610282.	1.1	3
10	Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence. <i>Antioxidants</i> , 2020, 9, 1226.	2.2	40
11	Reappraisal on pharmacological and mechanical treatments of heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 55.	2.7	27
12	Negative synergism of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2027-2038.	0.7	12
13	Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 219-234.	1.7	2
14	Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2020, 13, e006685.	1.6	21
15	Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus. <i>Theranostics</i> , 2020, 10, 2675-2695.	4.6	37
16	Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE. <i>Cardiovascular Diabetology</i> , 2020, 19, 106.	2.7	10
17	Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. <i>Heart Rhythm</i> , 2020, 17, 1025-1033.	0.3	34
18	Editor-in-Chief's Top Picks From 2019. <i>Journal of the American College of Cardiology</i> , 2020, 75, 776-834.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 1168-1177.	1.4	14
20	Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 1325-1338.	1.8	28
21	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 435-444.	0.7	6
22	The Arrhythmogenic Impact of Heart Failure With Preserved Ejection Fraction on Diabetics. <i>American Journal of Cardiology</i> , 2021, 141, 149-150.	0.7	0
23	How Diabetes and Heart Failure Modulate Each Other and Condition Management. <i>Canadian Journal of Cardiology</i> , 2021, 37, 595-608.	0.8	10
24	Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. <i>British Journal of General Practice</i> , 2021, 71, e62-e70.	0.7	13
25	Cardiorespiratory fitness in patients with type 2 diabetes: A missing piece of the puzzle. <i>Heart Failure Reviews</i> , 2021, 26, 301-308.	1.7	12
26	Cellular and molecular pathobiology of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2021, 18, 400-423.	6.1	198
27	Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community. <i>Cardiovascular Diabetology</i> , 2021, 20, 22.	2.7	13
28	Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 25.	2.7	27
29	Heart Failure With Preserved Ejection Fraction. , 2021, , 201-222.		0
30	HFpEF: Should We Consider Diabetic Patients Separately?. <i>Journal of the American College of Cardiology</i> , 2021, 77, 420-422.	1.2	6
31	Beyond the myocardium: Sodium-glucose cotransporter-2 inhibitors in heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1215-1218.	2.2	0
32	Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort. <i>Cardiovascular Diabetology</i> , 2021, 20, 48.	2.7	24
33	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 89-99.	1.9	18
34	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
35	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. <i>Annals of Translational Medicine</i> , 2021, 9, 523-523.	0.7	1
36	CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia. <i>Circulation Research</i> , 2021, 129, 98-113.	2.0	38

#	ARTICLE	IF	CITATIONS
37	Heart Failure And Diabetes: Perspective Of A Dangerous Association. <i>Current Hypertension Reviews</i> , 2021, 17, 85-93.	0.5	2
38	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1233-1243.	0.8	16
39	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	1
40	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100933.	3.2	67
41	In vivo reprogramming as a new approach to cardiac regenerative therapy. <i>Seminars in Cell and Developmental Biology</i> , 2022, 122, 21-27.	2.3	12
42	Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3484.	1.7	6
43	A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Study. <i>Cardiovascular Diabetology</i> , 2021, 20, 136.	2.7	9
44	Neutrophils pro-inflammatory and anti-inflammatory cytokine release in patients with heart failure and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3855-3864.	1.4	9
45	Chronic low-grade inflammation in heart failure with preserved ejection fraction. <i>Aging Cell</i> , 2021, 20, e13453.	3.0	33
46	Association between cortisol and left ventricular diastolic dysfunction in patients with diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2022, 13, 344-350.	1.1	8
47	Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 698117.	1.1	7
48	SIRT5-Related Desuccinylation Modification Contributes to Quercetin-Induced Protection against Heart Failure and High-Glucose-Prompted Cardiomyocytes Injured through Regulation of Mitochondrial Quality Surveillance. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-17.	1.9	43
49	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 0, , .		4
50	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113904.	6.6	49
51	Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2021, 20, 185.	2.7	13
52	FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin $\beta_1$ /p125-AKT signaling and reduction of oxidative/nitrosative stress. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 27-41.	0.9	41
53	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. , 2021, , 463-472.		0
54	Consensus document: management of heart failure in type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2021, 26, 1037-1062.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 63-74.	1.1	9
56	CRP Induces NETosis in Heart Failure Patients with or without Diabetes. <i>ImmunoHorizons</i> , 2019, 3, 378-388.	0.8	28
57	Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology. <i>Korean Circulation Journal</i> , 2020, 50, 1051.	0.7	15
58	On the search for the right definition of heart failure with preserved ejection fraction. <i>Cardiology Journal</i> , 2020, 27, 449-468.	0.5	13
59	Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?. <i>Current Cardiology Reports</i> , 2021, 23, 171.	1.3	2
60	Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 656536.	1.1	13
61	Research Progress of Heart Failure with Preserved Ejection Fraction. <i>Advances in Clinical Medicine</i> , 2021, 11, 4831-4840.	0.0	0
62	Lower B-type natriuretic peptide levels predict left ventricular concentric remodelling and insulin resistance. <i>ESC Heart Failure</i> , 2022, 9, 636-647.	1.4	6
63	Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis. <i>Hellenic Journal of Cardiology</i> , 2022, 64, 58-66.	0.4	7
64	Mitophagy Disequilibrium, a Prominent Pathological Mechanism in Metabolic Heart Diseases. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4631-4640.	1.1	9
65	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. <i>Biomolecules</i> , 2022, 12, 176.	1.8	20
66	Transforming growth factor- $\beta^2$ in myocardial disease. <i>Nature Reviews Cardiology</i> , 2022, 19, 435-455.	6.1	87
67	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. <i>Diabetes Therapy</i> , 2022, 13, 241-250.	1.2	11
68	Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 2022, 24, 109-117.	2.0	4
69	Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF. <i>Heart Failure Reviews</i> , 2022, 27, 609.	1.7	2
70	Diabetes-Induced Cellular Senescence and Senescence-Associated Secretory Phenotype Impair Cardiac Regeneration and Function Independently of Age. <i>Diabetes</i> , 2022, 71, 1081-1098.	0.3	30
71	Capillaries as a Therapeutic Target for Heart Failure. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 971-988.	0.9	4
72	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. <i>Frontiers in Physiology</i> , 2021, 12, 785879.	1.3	3

#	ARTICLE	IF	CITATIONS
73	Coronary microvascular dysfunction and findings of heart failure with preserved ejection fraction in patients with microvascular angina. <i>Minerva Medica</i> , 2022, , .	0.3	2
74	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-10.	1.0	1
75	Global status and trends in heart failure with preserved ejection fraction over the period 2009-2020. <i>Medicine (United States)</i> , 2022, 101, .	0.4	1
76	Serum-Induced Expression of Brain Natriuretic Peptide Contributes to Its Increase in Patients with HFpEF. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2991.	1.8	1
77	Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer. <i>Journal of the American Heart Association</i> , 2022, 11, e023895.	1.6	1
79	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1016-1030.	0.7	5
80	Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2022, 19, 63-74.	1.3	5
81	Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes—Findings from the Look AHEAD Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 2489-2497.	1.7	9
82	Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups.. <i>EXCLI Journal</i> , 2022, 21, 487-518.	0.5	3
83	Revelation of subclinical left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus using 2016 ASE/ EACVI guidelines. <i>Caspian Journal of Internal Medicine</i> , 2021, 12, 586-592.	0.1	3
84	Impact of Diabetic Retinopathy on Prognosis of Patients with Heart Failure with Preserved Ejection Fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	1.1	0
85	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	16
86	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 149.	0.8	7
87	Relationship between adipose tissue distribution and arterial stiffness in HFpEF. <i>Nutrition</i> , 2022, 102, 111726.	1.1	5
89	Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models. <i>JACC Basic To Translational Science</i> , 2022, 7, 844-857.	1.9	11
90	Heart failure with normal LVEF in BIOSTAT-CHF. <i>International Journal of Cardiology</i> , 2022, 364, 85-90.	0.8	1
91	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. <i>European Journal of Internal Medicine</i> , 2022, 103, 29-35.	1.0	5
92	Effects of glycemic traits on left ventricular structure and function: a mendelian randomization study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	6

#	ARTICLE	IF	CITATIONS
93	Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. <i>International Journal of Medical Sciences</i> , 2022, 19, 1118-1121.	1.1	4
94	The future of heart failure with preserved ejection fraction. <i>Herz</i> , 2022, 47, 308-323.	0.4	12
95	What dietary interventions have been tested in heart failure with preserved ejection fraction? A systematic scoping review. <i>European Journal of Cardiovascular Nursing</i> , 2023, 22, 126-140.	0.4	3
96	Neutrophils and Circulating Inflammatory Biomarkers in Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2022, 178, 80-88.	0.7	1
97	The Diabetic Cardiorenal Nexus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7351.	1.8	6
98	Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. <i>Cardiovascular Research</i> , 2023, 118, 3434-3450.	1.8	49
99	Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 116-122.	1.3	42
100	The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure. <i>Biomedicines</i> , 2022, 10, 1751.	1.4	5
102	Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 2999-3006.	4.3	9
103	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. <i>Herz</i> , 0, , .	0.4	1
104	Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 327-340.	1.1	4
106	Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. <i>Circulation</i> , 2022, 146, 676-686.	1.6	46
107	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
108	Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction. <i>Cardiology Clinics</i> , 2022, 40, 397-413.	0.9	6
109	SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes. <i>Circulation Research</i> , 2022, 131, 926-943.	2.0	18
110	Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> .the. 2022. 10. 869-881.	5.5	15
111	Oncometabolism: A Paradigm for the Metabolic Remodeling of the Failing Heart. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13902.	1.8	2
112	Blocking MG53 <sup>S255</sup> Phosphorylation Protects Diabetic Heart From Ischemic Injury. <i>Circulation Research</i> , 2022, 131, 962-976.	2.0	8

#	ARTICLE	IF	CITATIONS
113	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46.		9
115	The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus. Cardiovascular Diabetology, 2022, 21, .	2.7	5
116	Microvascular Disease and the Pathogenesis of Heart Failure in Diabetes: A Tiny Piece of the Tricky Puzzle. Diabetes Care, 2022, 45, 2817-2819.	4.3	3
117	Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
118	Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study. Open Heart, 2022, 9, e002133.	0.9	3
120	Evaluation of Microvascular Rarefaction in Vascular Cognitive Impairment and Heart Failure (CRUCIAL): Study Protocol for an Observational Study. Cerebrovascular Diseases Extra, 2023, 13, 18-32.	0.5	2
121	Streptozotocin-Induced Type 1 and 2 Diabetes Mellitus Mouse Models Show Different Functional, Cellular and Molecular Patterns of Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2023, 24, 1132.	1.8	19
122	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
123	Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database. International Journal of Cardiology, 2023, 378, 71-76.	0.8	0
124	SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials. Heart and Lung: Journal of Acute and Critical Care, 2023, 59, 109-116.	0.8	8
125	The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines, 2023, 11, 457.	1.4	5
126	Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction. CJC Open, 2023, 5, 380-391.	0.7	1
127	Diabetes Induces Cardiac Fibroblast Activation, Promoting a Matrixâ€Preserving Nonmyofibroblast Phenotype, Without Stimulating Pericyte to Fibroblast Conversion. Journal of the American Heart Association, 2023, 12, .	1.6	3
128	Association between triglyceride glucose index and subclinical left ventricular systolic dysfunction in patients with type 2 diabetes. Lipids in Health and Disease, 2023, 22, .	1.2	3
129	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2023, 81, 1835-1878.	1.2	74
138	Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes. Contemporary Diabetes, 2023, , 779-819.	0.0	0
148	Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery. Acta Pharmacologica Sinica, 2024, 45, 23-35.	2.8	2
176	Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia, 2024, 67, 574-601.	2.9	0



#	ARTICLE	IF	CITATIONS
---	---------	----	-----------